BioCardia, Inc. Share Price & Technical Analysis
BCDA · $0.95 (+4.40%)
Healthcare / Biotechnology
$0.95
+4.40%
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina re…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-9% return in May, -19% avg return in past 3 year May month.
-17% return in 2026, -65% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -8% | 8% | 0% | -8% | -9% | – | – | – | – | – | – | – | -17% |
| 25 | 14% | -13% | 25% | 19% | -21% | -9% | 5% | -5% | -32% | 8% | 7% | -20% | -22% |
| 24 | -33% | 21% | -28% | -8% | -21% | -35% | 0% | 0% | -3% | -26% | -4% | -8% | -145% |
| 23 | 21% | -11% | -11% | 5% | -13% | 44% | -62% | -22% | -45% | -15% | 72% | 9% | -29% |
| 22 | -3% | 12% | -2% | -24% | 3% | -15% | 2% | 28% | 0% | -6% | -6% | 18% | 9% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$12.09M
P/E ratio
—
52W high
$2.45
52W low
$0.84
Volume
65,322
Beta
0.55
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BioCardia, Inc. share price today?
- BioCardia, Inc. (BCDA) last traded around $0.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BCDA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BCDA. Download the app for real-time alerts.
- How can I analyze BioCardia, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.